Therapeutic interventions using neutralizing antibodies against C5a or C5aR and C5aR antagonists remain attractive targets for human disease models such as sepsis, cancer, inflammatory bowel disease, arthritis, and pregnancy-related complications [46], [47]. The gene discussed is C5AR1; the disease is arthritic joint disease.